# Nanjing Tengchen Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-tengchen-biotechnology-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.tengchenbio.com
- Latest round: Angel (Jun 14, 2018)
- Investors on record: 2

## About

Established in 2018 and based in Nanjing, China, Tantica is a biological technology company that focuses on development of tumor in diagnostic technology and products. The founder and CEO (Chief Executive Officer) Prof. Rongxi Yang received a PhD in molecular epidemiology from the German National Cancer Research Center in 2011 and has been a professor in the Department of Epidemiology, School of Public Health, Nanjing Medical University. She served as a researcher at the German National Cancer Research Center and Heidelberg University Medical School. The company has 1,600 square meters of R&D center and medical testing laboratory.

The company's main provides early cancer diagnosis, prognosis evaluation, curative effect evaluation and recurrence monitoring services for customers. The company's self-developed DNA methylation technology, research and development platform has the function of mark tumor biology, tumor treatment and cut off tumor invasion and metastasis. The company another product matrix-assisted laser desorption ionization time-of-flight mass spectrometry(MALDI-TOF MS)mainly used for clinical microbial identification, genotyping analysis, biomarker identification, pathogen identification and mass spectrometry imaging. The company has two product Feijieming and Feichangan, Feijieming is use to differential diagnosis test for benign and malignant pulmonary nodules and Feichangan is use to early lung cancer screening and testing.

## Funding rounds

- Angel, Jun 14, 2018 — Legend Star, Bohe Angel Fund

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Angel
- Bohe Angel Fund — Angel